Summary
Annually, cardiovascular disease (CVD) causes over 4m deaths in Europe and 17.3m deaths globally, and is expected to
grow to over 23.6m by 2030. It accounts for 40% of deaths in the EU and costs the EU economy almost €196bn each year.
2D ultrasound scans are currently the primary choice for vascular diagnostics. Due to low sensitivity, a limited field of action
and the lack of volume information, patients are often referred for CTa, MRa and catheter angiography for the detailed
imaging required for diagnosis and treatment planning. Referrals delay treatment, exposes the patient to risks associated
with radiation and contrast mediums and increases costs. This presents a need to improve the speed and safety of the
diagnosis of vascular conditions for rapid treatment, as well as to improve workflow efficiency and reduce costs. The project
consortium will further develop the piur tUS system, a 3D freehand tomographic US system capable of rapid, safe and
accurate reconstructive 3D quantifiable vascular imaging. It will provide a low cost and reproducible imaging solution that will
reduce the need for referrals and be an effective preventative screening tool for CVD. We aim to complete and publish the
results from 4 CVD clinical studies to generate the clinical evidence required for CE marking and clinical validation for market
uptake. The 4 clinical applications studied will provide a solution for conditions most frequently referred for detailed 3D
imaging to maximise the cost-benefit to clinics of purchasing the piur tUS system. The project consortium combines piur
imaging’s expertise in medical device development and commercialisation with 3D imaging specialist ImFusion GmbH and
medical device product development and manufacturing experts ACMIT. The clinical input for the product development and
the clinical studies will be provided by our consortium partners, Independent Vascular Services Ltd and the Institute for
Cardiovascular Science: University of Manchester
grow to over 23.6m by 2030. It accounts for 40% of deaths in the EU and costs the EU economy almost €196bn each year.
2D ultrasound scans are currently the primary choice for vascular diagnostics. Due to low sensitivity, a limited field of action
and the lack of volume information, patients are often referred for CTa, MRa and catheter angiography for the detailed
imaging required for diagnosis and treatment planning. Referrals delay treatment, exposes the patient to risks associated
with radiation and contrast mediums and increases costs. This presents a need to improve the speed and safety of the
diagnosis of vascular conditions for rapid treatment, as well as to improve workflow efficiency and reduce costs. The project
consortium will further develop the piur tUS system, a 3D freehand tomographic US system capable of rapid, safe and
accurate reconstructive 3D quantifiable vascular imaging. It will provide a low cost and reproducible imaging solution that will
reduce the need for referrals and be an effective preventative screening tool for CVD. We aim to complete and publish the
results from 4 CVD clinical studies to generate the clinical evidence required for CE marking and clinical validation for market
uptake. The 4 clinical applications studied will provide a solution for conditions most frequently referred for detailed 3D
imaging to maximise the cost-benefit to clinics of purchasing the piur tUS system. The project consortium combines piur
imaging’s expertise in medical device development and commercialisation with 3D imaging specialist ImFusion GmbH and
medical device product development and manufacturing experts ACMIT. The clinical input for the product development and
the clinical studies will be provided by our consortium partners, Independent Vascular Services Ltd and the Institute for
Cardiovascular Science: University of Manchester
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/760380 |
| Start date: | 01-05-2017 |
| End date: | 31-10-2019 |
| Total budget - Public funding: | 2 691 746,25 Euro - 2 091 204,00 Euro |
Cordis data
Original description
Annually, cardiovascular disease (CVD) causes over 4m deaths in Europe and 17.3m deaths globally, and is expected togrow to over 23.6m by 2030. It accounts for 40% of deaths in the EU and costs the EU economy almost €196bn each year.
2D ultrasound scans are currently the primary choice for vascular diagnostics. Due to low sensitivity, a limited field of action
and the lack of volume information, patients are often referred for CTa, MRa and catheter angiography for the detailed
imaging required for diagnosis and treatment planning. Referrals delay treatment, exposes the patient to risks associated
with radiation and contrast mediums and increases costs. This presents a need to improve the speed and safety of the
diagnosis of vascular conditions for rapid treatment, as well as to improve workflow efficiency and reduce costs. The project
consortium will further develop the piur tUS system, a 3D freehand tomographic US system capable of rapid, safe and
accurate reconstructive 3D quantifiable vascular imaging. It will provide a low cost and reproducible imaging solution that will
reduce the need for referrals and be an effective preventative screening tool for CVD. We aim to complete and publish the
results from 4 CVD clinical studies to generate the clinical evidence required for CE marking and clinical validation for market
uptake. The 4 clinical applications studied will provide a solution for conditions most frequently referred for detailed 3D
imaging to maximise the cost-benefit to clinics of purchasing the piur tUS system. The project consortium combines piur
imaging’s expertise in medical device development and commercialisation with 3D imaging specialist ImFusion GmbH and
medical device product development and manufacturing experts ACMIT. The clinical input for the product development and
the clinical studies will be provided by our consortium partners, Independent Vascular Services Ltd and the Institute for
Cardiovascular Science: University of Manchester
Status
CLOSEDCall topic
FTIPilot-01-2016Update Date
11-05-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Interoperability (ICT)
